Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BLASH......MUCL BREAKING OUT ?????
BIOM UP IN PRE MARKET
BEEN THERE.
YOU SHOULD HAVE SEEN SOME OF THE EMAIL I GOT .. I HAVENT BEEN THREATENED LIKE THAT SINCE VIET NAM .. FORTUNATELY I CANT KILL ANYONE WHEN THREATENED SINCE I WAS TRAINED TO RESPOND WITH A VENGANCE BACK THEN ....TOO MANY PEOPLE LOOKING FOR CONFRONTATIONS THESE DAYS .. THE WORLD WOULD BE A BETTER PLACE IF WE ALL JUST STEPPED BACK AND OBSERVED THE BEAUTY OF IT ONCE IN AWHILE......
SPOKEN LIKE A TRUE GENTLEMAN ...... THANK YOU .....
THANKS BLASH ..I GOT BLASTED FROM PEOPLE ON MACDADS SITE FOR SUGGESTING A STOCK AND WAS ACCUSED OF BEING A PUMPER .. THEY ALSO SENT ME SOME REAL NASTY AND PERSONAL EMAIL WITH ONE GUY THREATENING ME.. SO IM A LITTLE GUNSHY ABOUT POSTING ANYTHING ...JAKE
I DONT KNOW IF YOUR BEING SARCASTIC OR NOT ??? LOL
BLASH. YOU WATCHING MUCL ???
LENF just hit 11.00
Jan 06, 2005 (M2 PRESSWIRE via COMTEX) -- The Emerging Stock Report begins
coverage today on a very interesting and dynamic company that astute investors
should take note of. MultiCell Technologies, Inc., (OTCBB: MUCL), is a leading
provider of liver cell-based products for drug discovery and therapeutic
applications. MultiCell has leveraged its proprietary cell technologies to
engineer liver cell lines that retain their native functionality, continuously
regenerate, and are non-tumorigenic. This could also lead potentially to
development of adult stem cells. This means that MultiCell's cell lines may save
years of time and millions of dollars during preclinical drug discovery,
development and testing stages because the cell lines can be used instead of
animal or human testing.
In addition to selling hepatocytes to the pharmaceutical industry, it is
developing cell-based toxicological and drug screening tests.
Xenogenics Corporation, a majority-owned subsidiary, is a developmental stage
enterprise that owns all of the rights to the Sybiol(r) Bio-synthetic liver
device for which a patent is pending in 15 countries, including the United
States.
Predicting how a drug will behave in humans before clinical testing requires
sophisticated in vitro tests to complement in vivo tests. Early drug metabolism
models can help predict drug-drug interactions and help prioritize compound
selection for further development.
Drug induced liver injury is now the leading cause of liver failure in the U.S.
As drug recalls occur, and labor and animal costs rise, affordable early
screening is demanded.
MultiCell's immortalized human hepatocyte lines closely resemble primary human
liver cells in morphology and function. Hepatocytes express drug-metabolizing
enzymes that biotransform drugs or substances ingested into the body, so they
help predict the effect of a compound on human livers. MultiCell's cell lines
are sensitive to compounds that increase the expression of CYP3A4, an essential
feature of in vitro model systems when studying drug-drug interactions. They
eliminate the problem of limited supply and organ donor variability that
restrict the use of harvested human liver cells for enzyme induction, cellular
toxicity assays and other in vitro screening. The Emerging Stock Report feels
that The Company and their technology represent a very effective way to reduce
the tremendous costs in related drug testing and also hold promise in a range of
other areas. The Emerging Stock Report will continue to monitor the industry and
companies who are having an impact and report to astute investors.
ITS A CELL STOCK THAT I OWNED ONCE BEFORE AND MADE SOME MONEY WITH AND I WAS WONDERING IF IT WAS JUST GETTING SOME PLAY BECAUSE OF ASTM AND STEM ... I WAS JUST LOOKING FOR ANOTHER VIEW AND I RESPECT YOURS AND KENS .....THANKS, JAKE
BLASH......WHAT ARE YOUR THOUGHTS ON MUCL ??
GREAT CALL TUNA...
I GOT IN TOO AT .78 AFTER WATCHING IT ALL DAY ...
NICE CALL GUYS ON VASO GUYS .$1.36 NOW
VASO ABSOLUTELY FLYING NOW
VASO MOVING UP
EGHT UP 0.32 IN PRE MARKET
IIP RUNNING ON NEWS IN PREMARKET
KEN.. I CAN TRADE AFTER HOURS WITH TD WATERHOUSE AND AMERITRADE ..I BELIEVE UNTIL 7:00 PM AND IN THE MORNING STARTING AT 8:00AM. THE STIPULATION IS YOU MUST USE LIMIT ORDERS. THERE IS NO MARKET ORDERS............JAKE
KEN, YES I DID BUT I SOLD IT FOR 5.70 AFTERHOURS....
THANKS BLASH ....THE WAY IT TOOK OFF AT THE CLOSE I WAS HOPING FOR SOME NEWS AFTER HOURS ..MAYBE BEFORE THE BELL ....JAKE
THANKS FLOTA... I JUST FELT THAT EVERYONE LIKED IT SO MUCH AS A JANUARY PICK THAT IT WAS WORTH A SHOT AT THAT PRICE.....
THANKS BLASH..I HAD PICKED UP ANOTHER 500 SHARES AT THE DROP TO 5.00 TODAY ..... I JUST SOLD THEM AND FEEL GOOD ABOUT IT ...IM STILL HOLDING VASO THO AS I THINK THERE IS STILL SOME MORE UPSIDE .....JAKE
LSI 5.73 IN AFTERHOURS
LSI NEWS
LSI Logic raises 4th-quarter revenue outlook
Tue Jan 4, 2005 04:08 PM ET
SAN FRANCISCO, Jan 4 (Reuters) - LSI Logic Corp. (LSI.N: Quote, Profile, Research) , a maker of chips used in data storage and communications products, raised its fourth-quarter revenue target and said it expected a smaller net loss, citing strong storage and consumer demand.
Revenue in the quarter is now expected to reach $415 million to $420 million, from an earlier target of $360 million to $390 million, LSI said in a statement.
VASO MOVING AGAIN
CBEX ON THE MOVE
BLASH
YOUR THOUGHTS ON THESE TWO FOR JANUARY... SCON AND SMSI ..
LENF
GNLB FLYING IN PREMARKET
AVII
ALL OK BLASH.....THANKS
HI BLASHER
I CANNOT GET INTO THE WEBSITE USING THE PASSWORD YOU ORIGINALLY GAVE ME ..WOULD YOU EMAIL ME ANOTHER .THANKS, JAKE
GNLB FLYING AT THE CLOSE $1.35
GNLB 1.12 UP 19 %
THERE GOES GNLB
ASTM ON THE MOVE
ITRA
OUCH..PPHM TAKING IT ON THE CHIN AFTER HOURS...